Active surveillance in Canadian men with low-grade prostate cancer

CMAJ

Volumn 188, Issue 8, 2016, Pages E141-E147

  Cristea, Octav ^a,d   Lavallée, Luke T ^a,d   Montroy, Joshua ^b   Stokl, Andrew ^b   Cnossen, Sonya ^b   Mallick, Ranjeeta ^b   Fergusson, Dean ^b   Momoli, Franco ^b,c,d   Cagiannos, Illias ^a,d   Morash, Christopher ^a,d   Breau, Rodney H ^a,b,d  

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADVANCED CANCER; AGE; AGED; ARTICLE; CANADIAN; CANCER GRADING; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; DISEASE COURSE; FOLLOW UP; GLEASON SCORE; HEALTH SURVEY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MALE GENITAL SYSTEM; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE SURGERY; PROSTATECTOMY; RETROSPECTIVE STUDY; RISK FACTOR; ADULT; BIOPSY; BLOOD; CANADA; COMORBIDITY; MIDDLE AGED; PATHOLOGY; PROSTATIC NEOPLASMS;

ADULT; AGED; BIOMARKERS, TUMOR; BIOPSY; CANADA; COMORBIDITY; DIGITAL RECTAL EXAMINATION; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; POPULATION SURVEILLANCE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84968877328     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.150832     Document Type: Article

References (26)

1. Canadian Cancer Society Advisory Committee on Cancer Statistics. Canadian cancer statistics 2015. Toronto: Canadian Cancer Society; 2015.
2. Ilic D, Neuberger MM, Djulbegovic M. Screening for prostate cancer. Cochrane Database Syst Rev 2013;1:CD004720.
3. Moyer VA. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012;157:120-34.
4. Bell N, Connor-Gorber S, Shane A, et al. Recommendations on screening for prostate cancer with the prostate-specific antigen test. CMAJ 2014;186:1225-34.
5. Qaseem A, Barry MJ, Denberg TD, et al. Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med 2013;158:761-9.
6. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005;293:2095-101.
7. Klotz L, Emberton M. Management of low risk prostate cancer: active surveillance and focal therapy. Curr Opin Urol 2014;24:270-9.
8. Klotz L. Active surveillance for prostate cancer: overview and update. Curr Treat Options Oncol 2013;14:97-108.
9. Hayes JH, Ollendorf DA, Pearson SD, et al. Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA 2010;304:2373-80.
10. Wilcox CB, Gilbourd D, Louie-Johnsun M. Anxiety and health-related quality of life (HRQL) in patients undergoing active surveillance of prostate cancer in an Australian centre. BJU Int 2014;113 Suppl 2:64-8.
11. Satkunasivam R, Kulkarni GS, Zlotta AR, et al. Pathological, oncologic and functional outcomes of radical prostatectomy following active surveillance. J Urol 2013;190:91-5.
12. Klotz L, Vesprini D, Sethukavalan P, et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol 2015;33:272-7.
13. Klotz L. Active surveillance: patient selection. Curr Opin Urol 2013;23:239-44.
14. Reese AC, Landis P, Han M, et al. Expanded criteria to identify men eligible for active surveillance of low risk prostate cancer at Johns Hopkins: a preliminary analysis. J Urol 2013;190:2033-8.
15. Morash C, Tey R, Agbassi C, et al.; Active Surveillance Guideline Development Group. Active surveillance for the management of localized prostate cancer: guideline recommendations. Toronto: Cancer Care Ontario; 2015.
16. Population characteristics for Champlain Health Link Areas. Ottawa: Champlain LHIN; 2014. Available: www.champlainlhin.on.ca/∼/media/sites/champlain/Accountability/Integration/HL%20Docs/201410ChHLAsPopCharEN.pdf?la=en (accessed 2015 May 26).
17. Vellekoop A, Loeb S, Folkvaljon Y, et al. Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer. J Urol 2014;191:350-7.
18. El Hajj A, Ploussard G, de la Taille A, et al. Analysis of outcomes after radical prostatectomy in patients eligible for active surveillance (PRIAS). BJU Int 2013;111:53-9.
19. Hoffman KE, Niu J, Shen Y, et al. Physician variation in management of low-risk prostate cancer: a population-based cohort study. JAMA Intern Med 2014;174:1450-9.
20. Weerakoon M, Papa N, Lawrentschuk N, et al. The current use of active surveillance in an Australian cohort of men: a pattern of care analysis from the Victorian Prostate Cancer Registry. BJU Int 2015;115 Suppl 5:50-6.
21. Hager B, Kraywinkel K, Keck B, et al. Integrated prostate cancer centers might cause an overutilization of radiotherapy for low-risk prostate cancer: a comparison of treatment trends in the United States and Germany from 2004 to 2011. Radiother Oncol 2015;115:90-5.
22. Kates M, Tosoian JJ, Trock BJ, et al. Indications for intervention during active surveillance of prostate cancer: a comparison of the Johns Hopkins and Prostate Cancer Research International Active Surveillance (PRIAS) protocols. BJU Int 2015;115:216-22.
23. Dall'Era MA, Konety BR, Cowan JE, et al. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer 2008;112:2664-70.
24. Thomsen FB, Røder MA, Hvarness H, et al. Active surveillance can reduce overtreatment in patients with low-risk prostate cancer. Dan Med J 2013;60:A4575.
25. Klotz L. Active surveillance: the Canadian experience. Curr Opin Urol 2012;22:222-30.
26. Loeb S, Folkvaljon Y, Makarov DV, et al. Five-year nationwide follow-up study of active surveillance for prostate cancer. Eur Urol 2015;67:233-8.